Abstract
Purpose
Clear cell sarcoma (CCS) is a rare soft tissue tumor thought to originate from tendons and aponeuroses. This is the largest and most comprehensive study of CCS to the best of our knowledge. In addition, this is the first study to determine the estimated 10-year overall survival, specific treatment modalities including neoadjuvant and adjuvant combinations, and sites of distant metastasis in CCS utilizing a national database.
Methods
The National Cancer Database (NCDB) was used to study 489 patients diagnosed with CCS from 2004 to 2014. Kaplan–Meier methods were used to estimate 5- and 10-year overall survival, and log-rank tests were used to compare survival amongst stage.
Results
Median age at diagnosis was 39 years. Males and females were equally affected. Race distribution was 78% Caucasian and 15% Black. Most common primary site was lower limb or hip (53%). Percentage of patients with distant organ metastases was 15%, with lung being the most common site (4%). Median overall survival was 57.2 months. Overall estimated 5- and 10-year survival was approximately 50 and 38%, respectively. Approximate 5-year survival for Stages I–IV was 75, 65, 35, and 15%, respectively. Stages at disease presentation were 34% at Stage I, 13% at Stage II, 16% at Stage III, and 38% at Stage IV. Surgery was the most common form of treatment (83%); 34% received radiation and 20% received chemotherapy.
Conclusion
The 5-year overall survival for CCS in Stages III and IV was much worse than Stages I and II. Overall estimated 5- and 10-year survival was approximately 50 and 38%, respectively. Men and women were equally affected and had a median age at diagnosis of 39 years. The most common tumor location was lower limb and hip and the most common site of metastases was the lung.
Similar content being viewed by others
References
About the National Cancer Database. American College of Surgeons. http://www.facs.org/quality-programs/cancer/ncdb/about. Accessed 5 Nov 2017
Bianchi G, Charoenlap C, Cocchi S et al (2014) Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli. Eur J Surg Oncol 40:505–510
Bilimoria KY, Steward AK, Winchester DP, Ko CY (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683–690
Blazer DG, Lazar AJ, Xing Y, Askew RL, Feig BW, Pisters PWT et al (2009) Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the surveillance, epidemiology, and end results registry. Cancer 115(13):2971–2979
Chung EB, Enzinger FM (1983) Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol 7(5):405–413
Clark MA, Johnson MB, Thway K et al (2008) Clear cell sarcoma (melanoma of soft parts): the Royal Marsden Hospital experience. Eur J Surg Oncol 34:800–804
Cornillie J, van Cann T, Wozniak A, Hompes D, Schöffski P (2016) Biology and management of clear cell sarcoma: state of the art and future perspectives. Expert Rev Anticancer Thera 16(8):839–845
Enzinger FM (1965) Clear-cell sarcoma of tendons and aponeuroses. an analysis of 21 cases. Cancer 18:1163–1174
Heslin MJ, Lewis JJ, Woodruff JM, Brennan MF (1997) Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 4:425–431
Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T et al (2007) Clear cell sarcoma of tendons aponeuroses. Cancer 109(1):109–116
Lucas DR, Nascimento AG, Sim FH (1992) Clear cell sarcoma of soft tissues. mayo clinic experience with 35 cases. Am J Surg Pathol 16(12):1197–1204
Sara AS, Evans HL, Benjamin RS (1990) Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer 65(2):367–374
Participant User Files. American College of Surgeons. http://www.facs.org/quality-programs/cancer/ncdb/puf. Accessed 5 Nov 2017
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
M. Isabel Gonzaga declares no conflict of interest. Leah Grant, MD declares no conflict of interest. Christina Curtin declares no conflict of interest. Jonathan Gootee declares no conflict of interest. Peter Silberstein, MD declares no conflict of interest. Elida Voth, MD declares no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Gonzaga, M.I., Grant, L., Curtin, C. et al. The epidemiology and survivorship of clear cell sarcoma: a National Cancer Database (NCDB) review. J Cancer Res Clin Oncol 144, 1711–1716 (2018). https://doi.org/10.1007/s00432-018-2693-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-018-2693-6